BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype-Phase 2a results. (2022)

First Author: Zhang J

Attributed to: Elucidating how Dysbiosis, Senescence and Inflammatory Storms Impact Prostate Carcinogenesis and Treatment Resistance to Transform Care. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.2022.40.6_suppl.125

Publication URI: http://dx.doi.org/10.1200/jco.2022.40.6_suppl.125

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 6_suppl